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This Perspective proposes definitions for key terms in the field of HIV-1 latency and eradication. In the context
of eradication, a reservoir is a cell type that allows persistence of replication-competent HIV-1 on a timescale
of years in patients on optimal antiretroviral therapy. Reservoirs act as a barrier to eradication in the patient
population in which cure attempts will likely be made. Halting viral replication is essential to eradication,
and definitions and criteria for assessing whether this goal has been achieved are proposed. The cell types
that may serve as reservoirs for HIV-1 are discussed. Currently, only latently infected resting CD4+ T cells fit
the proposed definition of a reservoir, and more evidence is necessary to demonstrate that other cell types,
including hematopoietic stem cells and macrophages, fit this definition. Further research is urgently required
on potential reservoirs in the gut-associated lymphoid tissue and the central nervous system.Introduction
In 1997, it became possible for the first time to reduce plasma
HIV-1 levels to below the detection limit of clinical assays (50
copies of HIV-1 RNA/ml) with combinations of three antiretroviral
drugs (Perelson et al., 1997). This approach, known as highly
active antiretroviral therapy (HAART), dramatically decreased
deaths from HIV-1 infection (Palella et al., 1998). With millions of
life years saved because of it (Walensky et al., 2006), HAART is
amajor achievement ofmodernmedicine, converting a uniformly
fatal illness into one in which adherent patients starting treatment
early now have near-normal life expectancy (Mills et al., 2011).
The effective suppression of viremia initially inspired hopes
that the virus could be eradicated with 2–3 years of HAART (Per-
elson et al., 1997). However, in 1995, a latent form of HIV-1 infec-
tionwas demonstrated in vivo (Chun et al., 1995). A small fraction
of resting memory CD4+ T cells were shown to carry integrated
viral genomes. These cells do not release infectious virus in the
resting state but can do so following cellular activation (Chun
et al., 1995; Chun et al., 1997a). This latent reservoir in resting
CD4+ T cells persists even in patients on HAART who have no
clinically detectable viremia (Chun et al., 1997b; Finzi et al.,
1997; Wong et al., 1997). Longitudinal analysis demonstrated
that in patients on HAART, the time to eradication of the popula-
tion of latently infected cells would be over 60 years (Finzi et al.,
1999; Siliciano et al., 2003; Strain et al., 2003). This latent reser-
voir is now recognized as the major barrier to HIV-1 eradication
(Richman et al., 2009). Even patients who have been on HAART
for several years experience viral rebound within weeks of treat-
ment interruption (Davey et al., 1999), typically from an archival
variant (Joos et al., 2008). Life-long HAART is therefore required.
The latent reservoir for HIV-1 in resting CD4+ T cells differs in
important ways from classic forms of latency observed for
viruses such as those of the Herpesviridae family. For herpes
simplex viruses, latency allows immune evasion and viral persis-
tence between episodes of active replication (Perng and Jones,
2010). In contrast, in untreated HIV-1 infection, there is contin-uous viral replication throughout the disease course (Figure 1)
(Piatak et al., 1993). Rapid viral evolution allows escape from
neutralizing antibodies (Richman et al., 2003) and cytolytic
T lymphocyte (CTL) responses (Borrow et al., 1997) and provides
the principal mechanism of immune evasion.
Why, then, does latent HIV-1 infection occur? HIV-1 latency is
best viewed as an accidental consequence of viral tropism for
activated CD4+ T cells. Generally, infection leads to the rapid
death of activated CD4+ T cells (Ho et al., 1995; Wei et al.,
1995), but rarely, activated CD4+ T cells become infected as
they are reverting back to a resting memory state. Resting
CD4+ T cells aremuch less permissive for HIV-1 gene expression
due to profound differences in the transcriptional environment.
Thus, latency can be established. Latent HIV-1 is found in
resting memory CD4+ T cells but not in naive CD4+ T cells
(Brenchley et al., 2004a; Chomont et al., 2009; Chun et al.,
1997a; Pierson et al., 2000), supporting the idea that the cells
become infected during the transition from activated effectors
to resting memory cells. The establishment of latent infection is
a rare event; hence, the frequency of latently infected cells is
extremely low, typically around 1/106 resting CD4+ T cells
(Chun et al., 1997a; Finzi et al., 1997). Encountering antigen or
other activating stimuli can induce latently infected cells to
produce the virus, but the rate of virus production from this
and other stable reservoirs is typically <0.01% of the rate of virus
production due to ongoing replication in untreated patients
(Figure 1). Thus, this small pool of latently infected cells probably
plays only a minor role in the natural history of infection. Essen-
tially, HIV-1 latency is an epiphenomenon, but one that is
extremely important in the context of HAART because it repre-
sents a barrier to a cure. This view of latency has significant
implications for therapeutic efforts to purge the latent reservoir
cells and for the search for other HIV-1 reservoirs.
In addition to the latent reservoir in resting CD4+ T cells, there
is another important indication of viral persistence in patients on
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Figure 1. Plasma Virus Levels in Untreated and Treated HIV-1
Infection
Virus production continues throughout the course of untreated HIV-1 infection
(top panel). Levels of viremia vary widely between patients but average
between 10,000 and 100,000 copies/ml. Stable reservoirs make a very small
contribution to overall virus production. Their contribution, apparent only when
active replication is halted by HAART, is around 1 copy/ml (Palmer et al., 2003,
2008). HAART induces a rapid biphasic drop in the level of viremia (bottom
panel), reflecting the rapid turnover of the cells that produce most of the
plasma virus (Ho et al., 1995; Perelson et al., 1996, 1997; Wei et al., 1995).
Eradication strategies will likely be implemented in patients who have had
suppression of viremia to below the limit of detection for >1 year to allow decay
of these labile infected cell populations.
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copy/ml reveal trace levels of viremia in many patients (Dorna-
dula et al., 1999; Palmer et al., 2003, 2008). Because the half-
life of plasma virus is on the order of minutes (Perelson et al.,
1996; Ramratnam et al., 1999), this low-level viremia, referred
to as ‘‘residual viremia,’’ indicates ongoing virus production in
patients on HAART. At least some of these viruses appear to be
replication competent (Sahu et al., 2010). In principle, residual
viremia could result froma lowdegreeof ongoing viral replication,
the release of virus from latently infected cells that have become
activated, or the release of virus from other stable reservoirs.
Although the discovery of a stable latent reservoir for HIV-1
diminished hopes for eradication, the recent cure of a single378 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.patient using an ablative bone marrow transplantation strategy
has renewed interest in cure research (Hu¨tter et al., 2009). The
patient had stable suppression of viremia on HAART when he
developed acute myelogenous leukemia (AML). As part of the
treatment for AML, he received chemotherapy and radiation
followed by a bone marrow transplant from an HLA-matched
donor. The unique aspect of the case was the choice of a donor
who was also homozygous for a 32 base pair deletion in the
HIV-1 coreceptor CCR5. Thus, the patient’s hematopoietic
compartment was reconstituted with HIV-1-resistant cells. At
the time of initial transplantation, HAARTwas stopped, and there
has been no rebound in viremia for over 5 years. This patient is
thus considered to be the first and, to date, the only patient cured
of HIV-1 infection. Although this approach will be difficult to
generalize, the successful cure of a single patient has renewed
interest in the possibility of eradicating HIV-1 infection. The
purpose of this article is to precisely define the viral reservoirs
that represent a barrier to eradication.
Definitions
Discussions of HIV-1 eradication have been hindered by a lack of
precision and consensus regarding the meaning of key terms
such as latency, viral replication, reservoir, sanctuary, compart-
ment, and cure. Therefore, we propose here a set of definitions
that can be used as a starting point for refining the terminology
in cure research (Table 1).
Latency
The standard virologic definition of latency is a reversibly
nonproductive state of infection of individual cells. Latently
infected cells do not produce infectious virus particles but retain
the capacity to do so. Resting memory CD4+ T cells carrying
transcriptionally silent HIV-1 genomes clearly represent a form
of latency because a fraction of these cells produce infectious
virus following cellular activation (Chun et al., 1995, 1997a,
1997b; Finzi et al., 1997; Wong et al., 1997). The term latency
is sometimes used in clinical settings to refer to the prolonged
asymptomatic phase between acute infection and the develop-
ment of AIDS. This usage is incorrect because viral replication
continues throughout the course of untreated HIV-1 infection
(Figure 1) (Piatak et al., 1993).
Viral Replication
The first step in HIV-1 eradication is to stop the virus from repli-
cating. Surprisingly, there is considerable confusion regarding
the term ‘‘viral replication’’ and the measures that can be used
to determine whether replication has been halted by HAART.
Some authors erroneously equate virus production with viral
replication. The mere detection of viral RNA in cells from patients
on HAART does not demonstrate ongoing replication, nor does
the presence of residual viremia. Both can be explained by the
reactivation of latently infected cells (Figure 2). Virus production
by these cells can occur without new rounds of infection and
does not propagate the infection. We suggest that the term
‘‘replication’’ be used to mean new cycles of infection in which
previously uninfected cells become infected and produce virus
that goes on to infect additional cells.
Reservoir
Viral reservoirs have been defined as cell types or anatomical
sites in association with which replication-competent forms of




































Figure 2. Distinguishing Ongoing Viral Replication from Virus
Production by Latently Infected Cells that Have Been Activated
A variety of parameters have been evaluated to determine whether a low
degree of viral replication continues in patients on HAART. These are indicated
in red and include expression of HIV-1 RNA, residual viremia, labile products of
reverse transcription such as linear unintegrated HIV-1 DNA, LTR circles, and
the accumulation of mutations (viral evolution). Depending on the HAART
regimen, some of these parameters can also reflect the reactivation of latently
infected cells without further replication (bottom panel). For example, in
patients on regimens in which an integrase inhibitor is the most active drug, all
of these features except evolution would be present. Only the accumulation of
new mutations is uniquely characteristic of ongoing replication.
Table 1. Proposed Definitions for Key Terms in Eradication
Research
Term Brief Definition
Latency Reversibly nonproductive state of infection
of individual cells. Latently infected cells
retain the capacity to produce infectious
virus particles.
Viral replication New cycles of infection in which previously
uninfected cells become infected and
produce virus, which goes on to infect
additional cells. Evidence for viral replication
includes the presence of labile products of
reverse transcription, viral evolution during
prolonged HAART with drugs at therapeutic
concentrations, and a decrease in residual
viremia levels upon adding a fourth drug
to a HAART regimen.
Reservoir (previous
virologic definition)
Cell type or anatomical site, in association
with which a replication-competent form of
the virus persists with more stable kinetics




Infected cell population that allows
persistence of replication-competent
HIV-1 in patients on optimal HAART
regimens on the order of years.
Compartment An anatomical site for which there is limited
exchange of viral genetic information with
other sites; observable using phylogenetic
tools. May contain compartment-specific
viral sequences.
Sanctuary An anatomical site with suboptimal free
drug levels.
Cure: sterilizing Complete eradication of all replication-
competent forms of the virus.
Cure: functional Permanent viral suppression in the
absence of therapy to levels that prevent
immunodeficiency and transmission.
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There are two important elements to this definition. First, a reser-
voir allows persistence of some replication-competent form of
the virus capable of replenishing the pool of infected cells in
the future. Many HIV-1 genomes are defective, and thus the
detection of proviral DNA by PCR does not establish that a viral
reservoir is present. Second, there is a kinetic element to the
definition. Classic studies of viral dynamics in HIV-1 infection
(Ho et al., 1995; Perelson et al., 1996, 1997; Wei et al., 1995;
Zhang et al., 1999) established that most of the plasma virus is
produced by activated CD4+ T cells, which turn over very quickly
in the productively infected state (t1/2z 1 day). The mechanisms
by which the cells are cleared have not yet been elucidated and
may not involve direct lysis by CTL (Klatt et al., 2010; Wong et al.,
2010). The rapid death of these cells causes the precipitous drop
in viremia seen when new infection of susceptible cells is
blocked by HAART (Figure 1).
By the definition given above, any infected cell with a half-life
longer than 1 day could be considered a reservoir. Careful anal-
ysis of the rate of decay of viremia following the initiation ofHAART revealed a minor population of virus-producing cells
with a half-life of approximately 2 weeks (Perelson et al., 1997).
The nature of these cells is controversial. Productively infectedImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 379
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acute infection (Zhang et al., 1999), and in vitro studies suggest
that chemokines can render resting CD4+ T cells susceptible to
infection (Saleh et al., 2007). Macrophages are also infected
in vivo, but whether either of these cell types is responsible for
the second phase of decay remains unclear.
Eradication efforts will likely be attempted only in patients on
HAART who have had sustained suppression of viral replication
for years, and therefore the cells responsible for the second
phasemay not represent a barrier to eradication. Clinically signif-
icant reservoirs are more stable. This element of long-term
stability is captured in an elegant genetic definition of a viral
reservoir proposed by Nickle and colleagues (Nickle et al.,
2003). Because sequences arising at different time points in
the course of infection can be deposited and persist in a reser-
voir, the viral sequences in a reservoir will lack temporal structure
and show less mean divergence from the most recent common
ancestor (MRCA) than the contemporaneous pool of actively
replicating virus. The latent reservoir in resting CD4+ T cells
meets these criteria and can store the original wild-type
sequences as well as drug-resistant sequences arising due to
suboptimal therapy (Noe¨ et al., 2005; Persaud et al., 2000; Ruff
et al., 2002). Extensive sequence analysis is required to define
reservoirs in this way. We suggest that a simple and practical
definition for an HIV-1 reservoir is an infected cell population
that allows the persistence of replication-competent HIV-1 in
patients on optimal HAART regimens on a timescale of years.
To date, the latent reservoir in resting CD4+ T cells is the only
reservoir shown to fit this definition.
Sanctuaries and Compartments
There is also confusion over these terms. Both refer to anatomic
sites in which the virus may be present. Sanctuary is typically
used to refer to a site in which limited penetration of antiretroviral
drugs allows persistent replication. Whether there are sanctu-
aries of this kind in patients on HAART is unclear. Most studies
of pharmacologic sanctuaries measure the total drug concentra-
tion, including both protein-bound and -unbound forms of the
drug. However, according to the free drug hypothesis (Martin,
1965), only unbound forms distribute across membranes and
determine the biological effect. An important recent study has
shown that while the total concentration of the reverse transcrip-
tase inhibitor efavirenz (EFV) is much higher in the blood than in
the seminal plasma, the free EFV concentration is actually the
same (Avery et al., 2011). Thus, the male genital tract is actually
not a drug sanctuary for EFV, despite having much a lower total
EFV concentration. Similar arguments may apply to other puta-
tive drug sanctuaries such as the central nervous system
(CNS), and it is critical that free drug concentrations be
measured in these sites. Despite concerns about drug sanctu-
aries, there is no anatomical site where continued HIV-1 replica-
tion has been documented in the majority of patients.
Some antiretroviral drugs such as reverse transcriptase (RT)
and integrase inhibitors act intracellularly. Nucleoside analog
RT inhibitors (NRTIs) must be phosphorylated by cellular
enzymes to an active triphosphate form. Intracellular concentra-
tions of NRTIs correlate significantly with virological efficacy,
whereas plasma concentrations do not (for review, see Bazzoli
et al., 2010). Because of the technical barriers to sampling intra-
cellular drug concentrations in putative drug sanctuaries, other380 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.methods must be used to determine whether viral replication is
ongoing, as is discussed below.
The term compartment is sometimes used to refer to an
anatomical site in which the virus is present. More specifically,
it refers to a site that has limited exchange of viral genetic
information with other sites (Nickle et al., 2003). Compartments
can be identified using phylogenetic criteria. Typically there are
compartment-specific sequences—viral variants that evolve in
a particular site and are not distributed to other sites. The exten-
sive literature on compartmentalization of HIV-1 has been
recently reviewed (Blackard, 2012). Many early studies of
HIV-1 compartmentalization were flawed by PCR resampling
(Jabara et al., 2011). Compartments can only be defined with
adequate sampling of individual viral genomes in different sites.
HIV-1 compartmentalization has been explored mainly in un-
treated patients, and in terms of eradication, the key issue is
whether there are compartments that function as reservoirs.
Cure
Definitions for two types of cures have been proposed (Dieffen-
bach and Fauci, 2011). In a sterilizing cure, there is complete
eradication of the virus. In light of the high fraction of defective
viral genomes, this definition could be further refined as follows:
A sterilizing cure eliminates all replication-competent forms of
the virus; no viral reservoirs remain. By this definition, a patient
who retains some defective viral sequences would still be
considered cured. In a functional cure, there is permanent
control of viral replication without therapy. Elite suppressors
(ESs), patients who control viral replication without therapy, are
often considered examples of a functional cure (Deeks and
Walker, 2007). However, replication-competent virus can be iso-
lated from ESs (Blankson et al., 2007). In addition, it can be
shownwith sensitive assays (Pereyra et al., 2009) that these indi-
viduals have low-level viremia, analysis of which reveals
evidence for viral evolution (Bailey et al., 2006b; O’Connell
et al., 2010). Nevertheless, ESs generally maintain stable CD4+
T cell counts and plasma HIV-1 levels below the limit of detection
of clinical assays and are unlikely to transmit the virus. In this
light, a functional cure could be an intervention that renders
patients with progressive disease able to permanently control
viral replication to <50 copies/ml without therapy, thereby pre-
venting clinical immunodeficiency and transmission.
The Debate over Ongoing Virus Replication in Patients
on HAART
A critical issue is whether HAART completely stops viral replica-
tion. This issue has been difficult to resolve because some indi-
cators of viral replication can also reflect virus production from
stable reservoirs (Figure 2). Certain virologic measures could
provide conclusive evidence that HIV-1 replication is ongoing
in patients on HAART. The first is the detection of labile products
of reverse transcription (Zack et al., 1990). In patients on effec-
tive regimens composed of protease inhibitors, entry inhibitors,
and/or RT inhibitors, labile products of reverse transcription
should be absent. The final product of reverse transcription is
a full-length, linear, double-stranded viral DNA that is inserted
into host DNA by HIV-1 integrase. Pioneering studies by Mario
Stevenson showed that linear unintegrated HIV-1 DNA is a prev-
alent species in resting CD4+ T cells in untreated patients
(Bukrinsky et al., 1993). However, this form can be targeted by
Immunity
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(Pierson et al., 2002b; Zhou et al., 2005). Thus, the detection of
linear unintegrated HIV-1 DNA would indicate recent infection.
Linear unintegrated HIV-1 DNA has not been conclusively
demonstrated in patients on HAART. Circular forms of the viral
genome, specifically 1- and 2-LTR circles, can arise, particularly
when integration is blocked (Bukrinsky et al., 1993; Farnet and
Haseltine, 1991; Sharkey et al., 2000). These forms represent
dead ends with respect to replication but could serve as indica-
tors of recent infection if they are labile. However, the stability of
these forms is controversial (Butler et al., 2002; Pierson et al.,
2002a; Sharkey et al., 2005). In addition, as shown in Figure 2,
these forms could be generated through the activation of latently
infected cells in patients on regimens that rely on an integrase
inhibitor to provide most of the antiviral effect. In summary, the
analysis of unintegrated forms of the viral genome has not yet
provided unequivocal evidence for ongoing replication in most
patients on HAART.
Progressive evolutionary change is an inevitable characteristic
of HIV-1 replication due to the high error rate of RT (Mansky and
Temin, 1995). In each infected individual, one or a small number
of transmitted founder viruses evolve(s) over time into a complex
quasispecies (Keele et al., 2008; Wood et al., 2009). Thus,
ongoing evolution would also be a clear indication that HAART
does not completely stop replication. However, most studies
fail to detect evolution in the majority of patients on HAART
(Bailey et al., 2006a; Evering et al., 2012; Frenkel et al., 2003;
Kieffer et al., 2004). Analysis is complicated by variable adher-
ence in patient populations. In any population, there will be
patients with poor adherence in whom viral replication occurs
as a result of low drug levels. Thus, evolution in a small subset
of patients cannot be taken as evidence that the virus continues
to replicate in patients on optimal HAART regimens. There is no
study documenting evolutionary change in patients known to
have therapeutic levels of antiretroviral drugs. As discussed
above, residual viremia in patients on HAART reflects ongoing
virus production and might be expected to capture evolutionary
change if new cycles of replication were occurring. Interestingly,
detailed studies of residual viremia have shown that it is drug
sensitive, archival in character, and nonevolving (Bailey et al.,
2006a; Kieffer et al., 2004; Nettles et al., 2005; Persaud et al.,
2004). This lack of evolution is also consistent with the general
clinical experience that adherent patients can maintain suppres-
sion of viremia on HAART indefinitely.
A final experimental test of the hypothesis that viral replication
continues in patients on HAARTwould be the demonstration that
intensification of HAART with additional antiretroviral drugs
further reduces some measure of viral persistence. Numerous
studies with several different intensification drugs have all shown
that intensification has no effect on residual viremia (Dinoso
et al., 2009; Gandhi et al., 2010; Yukl et al., 2010b). These results
strongly suggest that residual viremia originates from stable
reservoirs rather than ongoing replication. A single study
suggests that intensification transiently increases the levels of
2-LTR circles in a subset of patients (Buzo´n et al., 2010), but in
light of uncertainty about the half-life of these circles, the signif-
icance of this result remains unclear.
In summary, the weight of the current evidence suggests that
HAART effectively halts ongoing viral replication as definedabove. This conclusion is supported by recent pharmacody-
namic studies that quantitate the inhibitory potential of HAART
regimens (Jilek et al., 2012). Clinical concentrations of some
antiretroviral drugs, specifically certain protease inhibitors, can
produce 10 logs of inhibition of a single round of infection, and
three-drug HAART regimens have an even higher combined
inhibitory potential. Given that there are only 1012 lymphocytes
in the entire body, only a small fraction of which are infected,
this degree of inhibition should effectively block all new infection
events in any drug-accessible region of the body. An interesting
recent paper suggests that in the vicinity of a virus-producing
cell, the exposure of adjacent cells to multiple infection events
reduces the efficacy of antiretroviral drugs on a probabilistic
basis (Sigal et al., 2011). However, cells with multiple proviruses
are rare in vivo (Josefsson et al., 2011). Any replication that does
continue in adherent patients on HAART is sufficiently limited
that resistance does not evolve. The success of HAART at block-
ing replication has led to a shift in the HIV-1 treatment field away
from the development of new antiretroviral drugs and toward the
eradication of reservoirs (Richman et al., 2009).
The Latent Reservoir in Resting CD4+ T Cells
The mechanisms by which latent infection is established and
maintained in resting CD4+ T cells have been recently reviewed
(Karn, 2011; Richman et al., 2009; Siliciano and Greene, 2011)
andwill be only briefly summarized here. In resting cells, an inter-
related set of changes in the transcriptional environment prevent
viral gene expression. These include both the sequestration of
critical host transcription factors and epigenetic modifications
that inhibit transcription. The transcription factors NFkB and
NFAT, both of which are involved in HIV-1 gene expression,
are excluded from the nucleus in resting CD4+ T cells (Bo¨hnlein
et al., 1988; Nabel and Baltimore, 1987). In addition, in resting
cells there is also sequestration of pTEFb, a complex of CDK9
and cyclin T1 that, in association with the HIV-1 protein Tat,
promotes elongation of HIV-1 transcripts (Contreras et al.,
2007; Kao et al., 1987; Peterlin and Price, 2006; Zhu et al.,
1997). Even though HIV-1 proviruses are typically integrated
within genes that are actively transcribed in resting CD4+
T cells (Han et al., 2004; Shan et al., 2011), repressive chromatin
modifications of nucleosomes and DNAmethylation at the HIV-1
LTR can interfere with expression of viral genes (Blazkova et al.,
2009; Van Lint et al., 1996; Ylisastigui et al., 2004). Many of these
mechanisms have been elucidated using transformed cell lines,
and the relative importance of each mechanism in maintaining
latency in vivo is unclear. The reversal of latency in vivo with
agents designed to target these mechanisms may provide
insight into this critical issue.
Several approaches to curing HIV-1 infection have been
proposed (reviewed in Durand et al., 2012a). One involves reac-
tivation of latent virus while patients are on HAART. This could
cause death of infected cells from viral cytopathic effects or
could allow the immune system to act against these cells.
Classes of small molecules capable of reactivating latent HIV-1
include histone deacetylase inhibitors such as vorinostat (suber-
oylanilide hydroxamic acid, SAHA) (Archin et al., 2009; Contreras
et al., 2009) and phorbol esters such as bryostatin and prostratin
that induce transcription of HIV-1 through activation of the
cellular protein kinase C pathway (Korin et al., 2002; KulkoskyImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 381
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clinical study demonstrated increased HIV-1 RNA expression in
resting CD4+ T cells of patients on HAART after a single oral dose
of SAHA, suggesting that SAHA is capable of perturbing the
latent reservoir in vivo (Archin et al., 2012). However, recent
evidence indicates that simply reactivating latent HIV-1 may
not be sufficient to induce immune-mediated purging of latent
reservoirs (Shan et al., 2012). Ex vivo experiments have shown
that priming of CD8+ T cells with HIV-1 gag peptides permits
these cells to kill HIV-1-infected CD4+ T cells whose virus had
been reactivated with SAHA, suggesting that a combination of
immune priming and reactivation of latent HIV-1 may be neces-
sary for a cure.
As approaches for targeting the latent reservoir are developed,
it is important to understand how the reservoir is measured. The
original in vivo measurements of the latent reservoir in resting
CD4+ T cells were made using a viral outgrowth assay (Chun
et al., 1997a; Finzi et al., 1997). In this assay, serial dilutions of
purified resting CD4+ T cells from an HIV-1 infected individual
are activated with the mitogen phytohemagglutinin (PHA) and
irradiated allogeneic peripheral blood mononuclear cells. This
causes uniform T cell activation and thereby switches all of
the cells carrying latent HIV-1 genomes into a state that is
permissive for virus gene expression. CD4+ T lymphoblasts
from healthy donors are added to amplify any virus released
from the infected cells, and after a period of 2–3 weeks, the
numbers of culture wells at each dilution that are positive for viral
growth is determined by ELISA assay for HIV-1 p24 antigen.
Using Poisson statistics, the number of positive wells can be
used to calculate the number of latently infected cells per million
resting CD4+ T cells (infectious units per million, IUPM). The
advantage of this assay is that it quantifies the minimum number
of latently infected cells harboring replication-competent virus.
Disadvantages include cost and complexity and the fact that
it does not distinguish between cells carrying integrated provi-
ruses and recently infected cells carrying linear unintegrated
HIV-1 DNA. However, because linear forms are labile, they
may not confound the measurement in patients on HAART.
The most serious problem is the dynamic range, which is limited
by the low frequency of latently infected cells and the large
amount of blood required to detect them. Eradication
approaches that produce only small (1 log) reductions in the
size of the latent reservoir may render the reservoir undetectable
with this assay.
Alternative assays use PCR to quantify cells containing viral
genomes. Some PCR assays are specific for integrated provi-
ruses (Chun et al., 1995, 1997a; O’Doherty et al., 2002). A
problem with all PCR-based assays is that they do not differen-
tiate between cells that can produce infectious virus and
cells containing proviruses that have been either permanently
silenced through epigenetic mechanisms or rendered noninfec-
tious through APOBEC3G-mediated hypermutation or some
other form of mutation (Chun et al., 1997a; Kieffer et al., 2005).
In patients on HAART, the frequency of resting CD4+ T cells
carrying HIV-1 DNA is 100- to 300-fold greater than the
frequency latently infected cells detected in the culture assay
(J. Siliciano et al., personal communication). Thus, although
PCR assays are simpler, it is not yet clear that they will provide
an effective way to monitor eradication efforts.382 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.Other Reservoirs
Although the existence of a stable latent reservoir in resting CD4+
T cells is clearly established, additional reservoirs could further
complicate eradication efforts. Evidence for additional reservoirs
comes from a detailed analysis of residual viremia. Although
many viral sequences in the plasma of patients on HAART are
identical to sequences found in the latent reservoir, the residual
viremia in some patients is dominated by oligoclonal populations
called predominant plasma clones (PPC) that are profoundly
underrepresented among proviruses in circulating CD4+ T cells
(Bailey et al., 2006a). Sophisticated genetic tests for population
structure also suggest that some of the residual viremia origi-
nates from cells other than resting CD4+ T cells found in the
circulation (Bailey et al., 2006a; Sahu et al., 2009). It is also
possible that these clonal sequences originate from resting
CD4+ T cells present only at low frequency in the circulation (An-
derson et al., 2011). In any event, residual viremia provides an
important window into the state of virologic suppression
because it reveals ongoing virus production in patients on
HAART and thus reports on the existence and persistence of viral
reservoirs.
Macrophages
Among other cell types that could serve as HIV-1 reservoirs,
macrophages are frequently mentioned. Early studies demon-
strated HIV-1 infection of macrophages in vivo and showed
that these cells are more resistant to viral cytopathic effects
than are activated CD4+ T cells (Gartner et al., 1986; Koenig
et al., 1986). Macrophage-tropic HIV-1 variants utilize the
CCR5 coreceptor (Alkhatib et al., 1996; Deng et al., 1996) but
also have sequence changes in the Env protein that allow entry
into cells that express low amounts of CD4, including macro-
phages (Schnell et al., 2011; Walter et al., 2005). Infection of
macrophages is particularly prominent late in the course of
infection, when most of the CD4+ T cells have been lost (Igarashi
et al., 2001). Although infected macrophages play a role in HIV-1
pathogenesis, it is not yet clear that these cells fit the definition
proposed above for a reservoir.
Infection of macrophages should be viewed in the context of
the normal differentiation of these cells (reviewed in Auffray
et al., 2009; Shi and Pamer, 2011). Macrophages are derived
from the pluripotent hematopoietic stem cells (HSCs) that give
rise to all cellular components of the blood. HSCs give rise to
hematopoietic progenitor cells (HPCs) with more restricted
differentiation potential, including a common myeloid progenitor
that gives rise to the granulocyte and monocyte-macrophage
lineages through an integrated process of proliferation and
differentiation occurring in the bonemarrow (Iwasaki and Akashi,
2007). The bone marrow phase of macrophage differentiation
lasts 2–5 days and ends when promonocytes leave the marrow
and enter the circulation as monocytes. Monocytes can be
divided into subsets based on expression of chemokine recep-
tors and other surface proteins, trafficking patterns, and differen-
tiation potential (Auffray et al., 2009; Shi and Pamer, 2011). After
less than 1 day, monocytes leave the circulation and undergo
further differentiation. This differentiation is tissue specific in
the sense that it results in the generation of cells with different
morphologies and functions, depending on the tissue. These
tissue forms include ordinary tissue macrophages, dendritic
cells, Langerhans cells in the epidermis, alveolar macrophages
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and microglial cells in the CNS, and osteoclasts in bone. The
tissue half-lives of these cell types are not well studied. Impor-
tantly, there is evidence that Langerhans cells and microglial
cells take up residence in their respective anatomic sites and
persist with less need for continuous replacement by monocytes
(Saijo and Glass, 2011).
Macrophages could in principle be infected at three different
stages: during differentiation in the marrow, in the blood as
monocytes, or in the tissues as mature macrophages. Infection
of HPCs in the marrow is discussed below. Little is known about
infection of bone marrow progenitor cells committed to the
monocyte-macrophage lineage, but if it does occur, it must be
rare. The number of circulating monocytes carrying HIV-1 DNA
is extremely low—so low, in fact, that contaminating CD4+
T cells cannot be excluded as a source of the signal (Zhu et al.,
2002). Monocytes appear to be relatively resistant to in vitro
infection with HIV-1 due to inefficient entry and delays in early
steps in the life cycle (Arfi et al., 2008). In addition, the recently
identified host restriction factor SAMHD1may protect these cells
from infection (Laguette et al., 2011). Neither monocytes nor any
of the committed progenitors in the marrow can be considered
reservoirs by the definition proposed in Table 1 because these
are transient stages of differentiation lasting only a matter of
days before further differentiation occurs. In contrast, macro-
phages could serve as a reservoir if they can persist in an in-
fected state on a timescale of years in patients on HAART.
Most studies documenting HIV-1 infection of macrophages in
various tissues were from the pre-HAART era (Hufert et al.,
1993; Koenig et al., 1986; McIlroy et al., 1996; Wiley et al.,
1986). Proving that macrophages function as a reservoir will
require definitive demonstration that these cells harbor replica-
tion-competent HIV-1 in patients who have had prolonged
suppression of viremia on HAART.
Hematopoietic Progenitor Cells
Hematopoietic progenitor cells (HPCs) express low amounts of
CD4 and the coreceptors required for HIV-1 entry, CCR5 and
CXCR4. Most studies have concluded that these cells do not
harbor HIV-1 in vivo (reviewed in McNamara and Collins,
2011). Recently, Carter et al. (2010) reported HIV-1 infection in
CD34+ HPCs in four of nine patients on HAART at a frequency
of 2.5–40 copies of HIV-1 DNA/104 cells. Interestingly, the infec-
tion remained latent until the cells were driven to differentiate. A
follow-up study indicated that CD133+ cord-blood-derived cells
were susceptible to in vitro infection, but only with X4-tropic virus
(Carter et al., 2011). Other, more recent, studies in patients on
HAART have used more rigorous purification of CD34+ cells
and have not detected HIV-1 DNA by PCR (Durand et al.,
2012b). It is therefore not clear that hematopoietic stem and
progenitor cells constitute a reservoir.
Anatomic Sites of HIV-1 Persistence
CNS
The CNS is an anatomic site in which viral replication has unique
pathophysiologic consequences. In the pre-HAART era, HIV-1-
associated dementia was a devastating consequence of the
disease (reviewed in Gonza´lez-Scarano and Martı´n-Garcı´a,
2005; McArthur et al., 2010). HIV-1 has been detected in several
areas of the brain as early as 15 days after infection (Davis et al.,1992). Within the CNS, infection is detected principally in peri-
vascular macrophages and microglial cells (Wiley et al., 1986).
There is strong evidence for compartmentalization of HIV-1 in
the CNS and concern that the CNS is a pharmacologic sanc-
tuary. CNS-specific viral variants can be demonstrated in un-
treated individuals and may be associated with dementia
(Schnell et al., 2010, 2011). With respect to the sanctuary issue,
drug concentrations in brain parenchyma are hard to assess, but
for some drugs, concentrations in the cerebrospinal fluid (CSF)
are substantially lower than in the blood. A sophisticated index
for the CNS penetration and effectiveness of antiretroviral drugs
has been developed (Letendre et al., 2008), but the best
predictor of neurocognitive disorders is the pretreatment CD4+
T cell count nadir (Heaton et al., 2010). Studies of drug concen-
trations in the CSF are subject to the same caveats mentioned
above for the male genital tract. Antiretroviral drugs are
substrates for a variety of transporters that could potentially
affect drug levels (reviewed in Varatharajan and Thomas,
2009). Arguing against the sanctuary concept is the general
finding that initiation of HAART rapidly reduces virus concentra-
tions in the CSF, generally to undetectable levels, and prevents
or improves many of the neurocognitive problems seen in
untreated HIV-1 infection (Price and Spudich, 2008). However,
there are rare patients in whom replication appears to continue,
as evidenced by detectable free virus in the CSF (Price and
Spudich, 2008). Given the prevalence of asymptomatic neuro-
cognitive impairment in patients on HAART (25%–50% in
some studies; Heaton et al., 2010), this is an extremely important
area for future research.
Compelling evidence for viral persistence in the CNS comes
from an elegant model of HIV-1-associated neurologic disease
in SIV-infected macaques (Zink and Clements, 2002). In this
model, infection with a neurovirulent SIV inoculum consistently
produces neurologic disease within months of infection in
untreated animals. Infection of microglial cells is particularly pro-
minent (Babas et al., 2003). Antiretroviral drugs rapidly reduce
plasma and CSF levels of virus and viral RNA in the brain paren-
chyma (Zink et al., 2010). Interestingly, levels of SIV DNA remain
constant. Because of the evidence from murine studies that
microglial cells turn over less rapidly than other monocyte-
derived cells (Saijo and Glass, 2011), there is concern that these
cells may serve as an important HIV-1 reservoir. The SIV model
affords the best opportunity to establish whether infected micro-
glial cells can persist on a timescale of years in the setting of
HAART.
Gut-Associated Lymphoid Tissue
A substantial fraction of the total lymphocytes in the body are in
specialized sites along the gastrointestinal tract. The gut-associ-
ated lymphoid tissue (GALT) includes the Peyer’s patches, orga-
nized lymphoid structures in the small intestine that function as
inductive sites. In addition, there are activated T cells in the
lamina propria layer of the intestinal mucosa, beneath the epithe-
lium. There are also lymphocytes within the epithelium. Pioneer-
ing studies by Veazey and colleagues in the SIV model (Veazey
et al., 1998) indicated that a dramatic loss of lamina propria
CD4+ T cells occurs early in infection, much earlier than the
loss of CD4+ T cells in other sites. The same is true for patients
with HIV-1 infection (Brenchley et al., 2004b; Guadalupe et al.,
2003). This appears to reflect the high frequency of laminaImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 383
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and that are in an activated state that is optimal for HIV-1 infec-
tion. The loss of CD4+ T cells from the lamina propria is not
rapidly reversed by HAART (Chun et al., 2008; Guadalupe
et al., 2003; Mehandru et al., 2006). In patients on HAART, the
fraction of CD4+ T cells in the lamina propria that carry HIV-1
DNA is substantially higher than in other sites (Chun et al.,
2008; Yukl et al., 2010a). Chun and colleagues reported an
average of approximately 5,000 HIV-1 DNA copies/106 CD4+
T cells in CD8-depleted biopsy samples from the terminal ileum
of patients on HAART, roughly five times greater than the HIV-1
DNA levels in resting CD4+ T cells from the peripheral blood.
These findings raise the issue of whether CD4+ T cells in the
GALT provide a unique reservoir for HIV-1. However, there are
unresolved issues. Because many CD4+ T cells in the gut are
in an activated state, it is important to know whether the infected
cells in this site are expressing viral RNA, and if so, whether
ongoing viral replication in this site contributes to the high level
of proviruses observed. A recent report describes a striking
lack of evolution in the proviral sequences from recto-sigmoid
biopsies (Evering et al., 2012). These results are inconsistent
with continuous viral replication in this site. It is also important
to determine the half-life of these infected cells and whether
they contribute to residual viremia and viral rebound following
treatment interruption.
Concluding Remarks
Recent developments have contributed to renewed optimism
that HIV-1 infection can be cured, but the discussion of this issue
has been hampered by lack of agreement regarding themeaning
of important terms. This review suggests definitions to facilitate
the discussion. The weight of evidence suggests that HIV-1
persistence in patients on HAART is due to long-lived infected
cells that function as a reservoir rather than viral replication
that continues despite HAART or in drug sanctuaries. Although
previous studies have proposed the existence of multiple reser-
voirs for HIV-1, only the latent reservoir in resting CD4+ T cells
meets the practical definition proposed here, a cell type in which
replication-competent virus can persist on a timescale of years in
patients on optimal HAART regimens. Macrophages are clearly
infected in vivo, but it is not yet clear that infected macrophages
in tissue sites survive on a timescale of years in patients on
optimal HAART regimens. It will be particularly important to
understand viral persistence in compartments such as the
CNS, where long-lived microglial cells may represent a reservoir,
and in the GALT, which is a major site of HIV-1 replication in
untreated individuals.
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